Erasca, Inc. (ERAS) News
Filter ERAS News Items
ERAS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ERAS News Highlights
- ERAS's 30 day story count now stands at 3.
- Over the past 9 days, the trend for ERAS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and MET are the most mentioned tickers in articles about ERAS.
Latest ERAS News From Around the Web
Below are the latest news stories about ERASCA INC that investors may wish to consider to help them evaluate ERAS as an investment opportunity.
3 Penny Stocks You’ll Regret Not Buying Soon: December EditionConsider the pros and cons of buying these penny stocks, which can deliver risk-adjusted returns to investors' portfolios. |
Erasca Co-Founder Acquires 3.2% More StockThose following along with Erasca, Inc. ( NASDAQ:ERAS ) will no doubt be intrigued by the recent purchase of shares by... |
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated MelanomaFirst-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal Phase 3 SEACRAFT-2 trial initiation in NRAS-mutated melanoma on track for H1 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused |
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash RunwayGained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose escalation and identified MTD for ERAS-801, supporting enrollment of expansion cohorts in recurrent GBM Extended cash runway to H1 2026 following strategic prioritization of programs SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company sin |
Erasca Reports Third Quarter 2023 Financial Results and Business UpdatesFirst patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, and marketable securities of $344 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driv |
Erasca to Present at Upcoming Investor Conferences in NovemberSAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in the following investor conferences in November 2023. Management will also participate in one-on-one investor meetings. Jefferies London Healthcare Conference (November 14 – 16, 2023) Location: Waldorf Hi |
With 31% ownership, Erasca, Inc. (NASDAQ:ERAS) has piqued the interest of institutional investorsKey Insights Institutions' substantial holdings in Erasca implies that they have significant influence over the... |
Insiders Are Betting Millions on These 2 Stocks — Here’s Why You Might Want to Follow Their LeadWhen stock markets are in flux, it’s time to dig a little deeper to find the right investments. Investors will look for all sorts of signs, based on the earnings forecasts or charts – but one of the clearest signs of all is put up by corporate insiders. These are the company officers who are charged with ensuring profits and returns. They are answerable to Boards of Directors and to shareholders, who expect them to build a company that supports a solid share value. These insiders, the C-suite re |
Insider Spends US$2.0m Buying More Shares In ErascaErasca, Inc. ( NASDAQ:ERAS ) shareholders (or potential shareholders) will be happy to see that the Co-Founder... |
Why Shares of Erasca Are Jumping TuesdayShares of Erasca (NASDAQ: ERAS) were up more than 12% as of 3 p.m. on Tuesday after a big insider buy. Erasca is a clinical-stage precision oncology company that focuses on RAS/MAPK pathway-driven cancers. Jonathan Lim, the chairman and CEO of Erasca, showed his confidence in the company by buying a million shares, with the transaction worth $2,025,999 in a filing reported to the U.S. Securities and Exchange Commission (SEC). |